Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Eicosapentaenoic acid + rosuvastatin
- Development stage
- Preclinical
- Lead developer
- Amarin
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Eicosapentaenoic acid + rosuvastatin is a fixed-dose combination therapy under development for the treatment of dyslipidemia and cardiovascular risk reduction. The combination includes ethyl eicosapentaenoic acid (EPA), an omega-3 fatty acid that reduces triglyceride levels, and rosuvastatin, a statin that inhibits HMG-CoA reductase to lower cholesterol synthesis. EPA acts by reducing hepatic very low-density lipoprotein (VLDL) triglyceride synthesis and secretion, while also exerting anti-inflammatory effects. Rosuvastatin competitively inhibits HMG-CoA reductase in the liver, leading to decreased cholesterol production and increased clearance of low-density lipoprotein (LDL) from the bloodstream. Clinical studies have shown that this combination can significantly stabilize non-obstructive neoatherosclerotic plaques compared to standard-dose statin monotherapy[2][3][5]. The product is being developed by Amarin.
- Brand names
- CrestorEpadelVascepa
- Other names
- ethyl eicosapentaenoic acid + rosuvastatin
02
Targets
HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)
Beyond the preview
Go deeper on Eicosapentaenoic acid + rosuvastatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Eicosapentaenoic acid + rosuvastatin.